Twist Bioscience's stock rose 0.9% following multiple announcements. The company entered into a licensing agreement with Invenra Inc. to become a co-exclusive provider of Invenra's B-Body bispecific antibody platform, expanding Twist's antibody discovery services. Additionally, Twist reported fiscal first quarter 2026 financial results showing record revenue of 103.7 million dollars, representing 17% growth compared to the prior year quarter. The company achieved a gross margin of 52.0%, up approximately 4 percentage points year-over-year. This marked the company's 12th consecutive quarter of sequential growth. Twist also raised its full-year revenue guidance to 435-440 million dollars and reiterated its Q4 fiscal 2026 adjusted EBITDA breakeven target.
Read full analysisTwist Bioscience's stock rose 0.9% following multiple announcements. The company entered into a licensing agreement with Invenra Inc. to become a co-exclusive provider of Invenra's B-Body bispecific antibody platform, expanding Twist's antibody discovery services. Additionally, Twist reported fiscal first quarter 2026 financial results showing record revenue of 103.7 million dollars, representing 17% growth compared to the prior year quarter. The company achieved a gross margin of 52.0%, up approximately 4 percentage points year-over-year. This marked the company's 12th consecutive quarter of sequential growth. Twist also raised its full-year revenue guidance to 435-440 million dollars and reiterated its Q4 fiscal 2026 adjusted EBITDA breakeven target.
Twist Bioscience manufactures synthetic DNA and provides tools for genomics research, drug discovery, and data storage applications. The company recently entered a co-exclusive licensing deal for Invenra's bispecific antibody platform and raised FY26 revenue guidance to $435M–$440M after reporting record Q1 revenue of $103.7 million with 52% gross margins. Today's new licensing agreement with a top-10 pharma company for its antibody discovery platform adds another commercial partnership to its expanding biologics services business.